|Articles|July 28, 2022

Boehringer Ingelheim to Use Seqster Platform

Patients in all studies can consent to longitudinal data use to accelerate RWE

Patient-centric healthcare data technology provider Seqster PDM, Inc. announced a three-year partnership with Boehringer Ingelheim to use the SeqsterOS to close the Real World Evidence (RWE) gap. To that end, SeqsterOS will provide patients in all of BI's studies access and engagement with longitudinal RWD, with full patient consent and control.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe

Related Content

Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention

ByMarcela Roy, MA, Lauren Crooks, MSc, Graham Ellis, MD, Alan Kott, MUDR, Dawie Wessels, MD, Elias Ketiar, MD, MRCP

June 4th 2026

For pharmaceutical and life sciences organizations, the strategic imperative is clear: begin immediately with foundation building, scale systematically with measurable milestones, and transform comprehensively toward AI-native data operations. Credit: Stock.Adobe.com/tippapatt.

The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck

ByPartha Anbil,Partha Khot

June 4th 2026

Boehringer Ingelheim to Use Seqster Platform

Related Content

A Shot in the Arm to Traditional Vaccine Trial Strategy

SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years

ACT Brief: Site-First Technology Strategy, AI Data Harmonization Architecture, and Obesity Trial Retention

Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention

The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck

Trending on Applied Clinical Trials Online

The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck

SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years

SCOPE X: The COPD Case Study That Shows What AI Can Do for Enrollment

A Shot in the Arm to Traditional Vaccine Trial Strategy

Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention